脂质体和脂质体可以被认为是优异的药物递送系统,因为它们能够装载所有化合物,无论是疏水性的还是亲水性的。此外,它们可以降低装载药物的毒性而不降低其有效性。集胞藻。是一个单细胞,淡水蓝藻菌株含有许多生物活性化合物,符合其在工业中的用途,Pharmaceutical,和许多其他领域。这项研究调查了纳米脂质体(L)和纳米脂质体(N)用于递送集胞藻的潜力。针对癌细胞系的提取物。使用干粉制剂和集胞藻属的乙醇提取物制备了四种不同类型的纳米颗粒。在纳米囊泡(分别为N1和N2)和脂质体(分别为L1和L2)中。使用ζ分析对形成的囊泡进行分析,SEM形态分析,和视觉检查证实了他们的稳定性和效率。在这项研究中,L1和L2的有效直径为419和847nm,分别,PDI值为0.24和0.27。此外,发现zeta电位范围为-31.6mV至-43.7mV。关于N1和N2,它们的有效直径为541nm和1051nm,分别,PDI值为0.31和0.35,zeta电位报告为-31.6mV至-22.2mV,分别。代谢谱分析从乙醇提取物中初步鉴定出22种代谢物(1-22)。在体外研究了其对代表性人类癌症的作用,特别针对结肠(Caco2),卵巢(OVCAR4),和乳腺癌(MCF7)细胞系。结果表明,制备的N1,N2,L1和L2对三种细胞系的潜在活性,其中L1对Caco2,OVCAR4和MCF7的细胞毒性IC50值分别为19.56,33.52和9.24µg/mL,而L2对Caco2,OVCAR4和MCF7的细胞毒性IC50值分别为26.27,56.23和19.61µg/mL.另一方面,N1表现出9.09、11.42和2.38µg/mL的IC50值,而N2对Caco2、OVCAR4和MCF7的值分别为15.57、18.17和35.31µg/mL。同时,该制剂对正常细胞系(FHC,OCE1和MCF10a)。所有化合物均针对表皮生长因子受体酪氨酸激酶(EGFR)进行计算机模拟评价。分子对接结果表明,化合物21(1-十六烷酰基-2-(9Z-十六烯酰基)-3-(6'-磺基-α-D-喹诺酮基)-sn-甘油),其次是化合物6(磺基喹诺酮基单酰基甘油),7(3-羟基肉豆蔻酸),8(糖脂PF2),12(棕榈油酸),和19(单硬脂酸甘油酯),显示出最高的结合亲和力。这些化合物与作为共结晶配体的关键氨基酸Lys721形成良好的氢键相互作用。这些结果表明,纳米脂质体和纳米脂质体负载了集胞藻。提取物对未来的癌症治疗发展充满希望。进一步的研究应该集中在临床试验上,稳定性评估,和药理学概况将这种方法转化为有效的抗癌药物。
Liposomes and
niosomes can be considered excellent drug delivery systems due to their ability to load all compounds, whether hydrophobic or hydrophilic. In addition, they can reduce the toxicity of the loaded drug without reducing its effectiveness. Synechocystis sp. is a unicellular, freshwater cyanobacteria strain that contains many bioactive compounds that qualify its use in industrial, pharmaceutical, and many other fields. This study investigated the potential of nano-liposomes (L) and nano-
niosomes (N) for delivering Synechocystis sp. extract against cancer cell lines. Four different types of nanoparticles were prepared using a dry powder formulation and ethanol extract of Synechocystis sp. in both nanovesicles (N1 and N2, respectively) and liposomes (L1 and L2, respectively). Analysis of the formed vesicles using zeta analysis, SEM morphological analysis, and visual examination confirmed their stability and efficiency. L1 and L2 in this investigation had effective diameters of 419 and 847 nm, respectively, with PDI values of 0.24 and 0.27. Furthermore, the zeta potentials were found to range from -31.6 mV to -43.7 mV. Regarding N1 and N2, their effective diameters were 541 nm and 1051 nm, respectively, with PDI values of 0.31 and 0.35, and zeta potentials reported from -31.6 mV to -22.2 mV, respectively. Metabolic profiling tentatively identified 22 metabolites (1-22) from the ethanolic extract. Its effect against representative human cancers was studied in vitro, specifically against colon (Caco2), ovarian (OVCAR4), and breast (MCF7) cancer cell lines. The results showed the potential activities of the prepared N1, N2, L1, and L2 against the three cell lines, where L1 had cytotoxicity IC50 values of 19.56, 33.52, and 9.24 µg/mL compared to 26.27, 56.23, and 19.61 µg/mL for L2 against Caco2, OVCAR4, and MCF7, respectively. On the other hand, N1 exhibited IC50 values of 9.09, 11.42, and 2.38 µg/mL, while N2 showed values of 15.57, 18.17, and 35.31 µg/mL against Caco2, OVCAR4, and MCF7, respectively. Meanwhile, the formulations showed little effect on normal cell lines (FHC, OCE1, and MCF10a). All of the compounds were evaluated in silico against the epidermal growth factor receptor tyrosine kinase (EGFR). The molecular docking results showed that compound 21 (1-hexadecanoyl-2-(9Z-hexadecenoyl)-3-(6\'-sulfo-alpha-D-quinovosyl)-sn-glycerol), followed by compounds 6 (Sulfoquinovosyl monoacylgycerol), 7 (3-Hydroxymyristic acid), 8 (Glycolipid PF2), 12 (Palmitoleic acid), and 19 (Glyceryl monostearate), showed the highest binding affinities. These compounds formed good hydrogen bond interactions with the key amino acid Lys721 as the co-crystallized ligand. These results suggest that nano-liposomes and nano-
niosomes loaded with Synechocystis sp. extract hold promise for future cancer treatment development. Further research should focus on clinical trials, stability assessments, and pharmacological profiles to translate this approach into effective anticancer drugs.